ARQL:NSD-ArQule, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.00

Change

0.00 (0.00)%

Market Cap

USD 2.42B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts. As of January 16, 2020, ArQule, Inc. operates as a subsidiary of Merck Sharp & Dohme Corp.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.11B 20.60 15.08
MRNA Moderna, Inc

N/A

USD52.85B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

N/A

USD49.45B 15.12 11.87
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.00B 55.18 32.28
BGNE BeiGene, Ltd

N/A

USD28.45B N/A N/A
SGEN Seagen Inc

N/A

USD27.06B 44.32 37.70
RPRX Royalty Pharma plc

N/A

USD25.83B 22.60 15.41
BNTX BioNTech SE

N/A

USD23.16B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD20.42B 26.59 3.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARQL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 1,036.36% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,036.36% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 135.35% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.35% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 156.21% N/A N/A N/A N/A
Risk Adjusted Return 86.64% N/A N/A N/A N/A
Market Capitalization 2.42B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.78 N/A N/A N/A N/A
Price / Cash Flow Ratio -186.17 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -19.98% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 16.58% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.48 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.